Full Press Release Details
"As the LUMINA data show, the Boston Scientific Illumina 3D Algorithm allows me to treat low back pain more consistently and effectively than before," said James North , M.D. of the Carolinas Pain Institute. "These data are impressive because they demonstrate sustained long term pain relief in an all-comers population; we did not exclude the type of challenging patients that physicians see every day."
Key findings of the study include:
LUMINA Spectra group
LUMINA Surgical group
LUMINA Physical Function group
About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, clinical data, and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
CONTACT: Media: Nisha Deo Media Relations Boston Scientific Corporation 408-893-9243 (cell) [email protected]
Investors: Susie Lisa , CFA Investor Relations Boston Scientific Corporation 508-683-5565 (office) [email protected]
SOURCE Boston Scientific Corporation